Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maze Therapeutics, Inc. - Common Stock (NQ:MAZE)

27.53 +0.05 (+0.18%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Maze Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight ↗
Small-cap stocks Ascentage Pharma, Maze Therapeutics, and Pagaya Technologies show improving fundamentals, strong cash positions, and bullish analyst ratings amid shifting investor interest. 
Via MarketBeat
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 ↗
The executive liquidated his entire direct holdings as the stock plunged about 50% from its 52-week high. 
Via The Motley Fool
Topics Regulatory Compliance
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Appointments to Its Board of Directors
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? ↗
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? ↗
This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases. 
Via The Motley Fool
News headline image
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials ↗
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Maze Therapeutics Announces $150 Million Registered Offering
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. ↗
This clinical-stage biotech focused on precision medicines for kidney and metabolic diseases just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33% ↗
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
Wednesday's session: top gainers and losers ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears ↗
This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings report. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗
a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise... 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge ↗
Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
News headline image
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock ↗
Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical... 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
What to Know About One Maze Insider's $3 Million Stock Sale as Shares Surge 150% ↗
This clinical-stage biotech focused on precision medicines reported significant insider selling, according to recent SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.